Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA Breakthrough Device-designated AI platform predicting sepsis mortality risk in emergency departments; $17.08M from Breyer Capital and YC generating $2.6M revenue at 13-person Burlington-based team.
Biocogniv is a Burlington, Vermont-based clinical AI company that has developed an FDA Breakthrough Device Designation-granted platform for predicting sepsis-related mortality and ICU admission risk in emergency departments — using AI analysis of routine clinical data (vital signs, lab values, patient history) to identify patients at highest risk of deterioration hours before clinical signs become obvious to clinicians, enabling earlier intervention in one of healthcare's most time-sensitive conditions. Founded in 2019 and a Y Combinator W20 graduate, Biocogniv raised $17.08 million from Breyer Capital and YC, generating $2.6 million in revenue in 2024 with a 13-person team.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.